Delayed onset of biologic or targeted synthetic dmards in rheumatoid arthritis patients and associated factors
Keywords:
access, treatment, rheumatoid arthritis
Abstract
Introduction: the goal of rheumatoid arthritis (RA) treatment is to obtain remission or low activity of the disease. In those patients who did not achieve this objective with conventional treatment, biologic or targeted synthetic disease-modifying anti- rheumatic drugs (bDMARD or tsDMARD, respectively) are indicated. The period of time between the prescription of these medications and its administration is variable.Objectives: to describe the delay time between the prescription of a bDMARD or tsDMARD and the administration of the rst dose, and its related reasons.References
I. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boum- pas D, Burmester G, et al. T2T Expert Committee. Trea- ting rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010 Apr;69(4):631-7.
II. Sociedad Argentina de Reumatología. Grupo de estudio de artritis reumatoidea. Actualización de las guías de práctica clínica en el tratamiento de la artritis reuma- toidea. Buenos Aires: Sociedad Argentina de Reumato- logía, 2013.
III. Smolen JS, Landewé R, Bijlsma J, Burmester G, Cha- tzidionysiou K, Dougados M, et al. EULAR recommen- dations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti- rheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977.
IV. Bartel G, Mayer M, Velez S, Daciuk N, Zazzeti F, Gómez A, et al. Acceso a biológicos en artritis reumatoidea ¿es po- sible el Treat To Target? (abstract). En: Rev Argent Reuma- tol Edición Especial Congreso. 49° Congreso Argentino de Reumatología; 2016 oct 19-22; Mendoza. p. 78.
V. Collado MV, Giorgis P, Kirmayr KI, Lencina M, Ponce Del- gado J, Rillo O, et al. Accesibilidad al tratamiento de los pacientes con artritis reumatoidea y su relación con factores sociales, culturales y económicos (abstract). En: Rev Argent Reumatol Suplemento Especial Congre- so. 52° Congreso Argentino de Reumatología; 2019 oct 16-19; Salta. p. 56.
VI. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classi - cation criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81.
VII. Citera G, Arriola MS, Maldonado-Cocco JA, Rosem- ffet MG, Sánchez MM, Goñi MA, et al. Validation and crosscultural adaptation of an argentine spanish ver- sion of the health assessment questionnaire disability index. J Clin Rheumatol 2004 Jun;10(3):110-5.
VIII. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modi ed disease activity scores that include twenty-eight-joint counts. Develop- ment and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 Jan;38(1):44-8.
IX. Lu CY, Macneill P, Williams K, Day R. Access to high cost medicines in Australia: ethical perspectives. Aust New Zealand Health Policy 2008 May 19;5:4.
X. Constitución de la Nación Argentina. 01-05-1853. Artículo 42.
XI. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheuma- toid arthritis to target: results of a systematic literatu- re search update. Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.
XII. Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the tar- get of remission in early rheumatoid arthritis is cost- effective: results of the DREAM registry. BMC Musculos- kelet Disord 2013 Dec 13;14:350.
XIII. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dou- gados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an inter- national task force. Ann Rheum Dis 2016 Jan;75(1):3-15.
XIV. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Working Group Equity in access to treatment of rheumatoid arthritis in Europe. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan;73(1):198-206.
XV. Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, et al. Access to biologic treatment for rheu- matoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011 Apr;17(4):SR1-13.
II. Sociedad Argentina de Reumatología. Grupo de estudio de artritis reumatoidea. Actualización de las guías de práctica clínica en el tratamiento de la artritis reuma- toidea. Buenos Aires: Sociedad Argentina de Reumato- logía, 2013.
III. Smolen JS, Landewé R, Bijlsma J, Burmester G, Cha- tzidionysiou K, Dougados M, et al. EULAR recommen- dations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti- rheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977.
IV. Bartel G, Mayer M, Velez S, Daciuk N, Zazzeti F, Gómez A, et al. Acceso a biológicos en artritis reumatoidea ¿es po- sible el Treat To Target? (abstract). En: Rev Argent Reuma- tol Edición Especial Congreso. 49° Congreso Argentino de Reumatología; 2016 oct 19-22; Mendoza. p. 78.
V. Collado MV, Giorgis P, Kirmayr KI, Lencina M, Ponce Del- gado J, Rillo O, et al. Accesibilidad al tratamiento de los pacientes con artritis reumatoidea y su relación con factores sociales, culturales y económicos (abstract). En: Rev Argent Reumatol Suplemento Especial Congre- so. 52° Congreso Argentino de Reumatología; 2019 oct 16-19; Salta. p. 56.
VI. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classi - cation criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81.
VII. Citera G, Arriola MS, Maldonado-Cocco JA, Rosem- ffet MG, Sánchez MM, Goñi MA, et al. Validation and crosscultural adaptation of an argentine spanish ver- sion of the health assessment questionnaire disability index. J Clin Rheumatol 2004 Jun;10(3):110-5.
VIII. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modi ed disease activity scores that include twenty-eight-joint counts. Develop- ment and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 Jan;38(1):44-8.
IX. Lu CY, Macneill P, Williams K, Day R. Access to high cost medicines in Australia: ethical perspectives. Aust New Zealand Health Policy 2008 May 19;5:4.
X. Constitución de la Nación Argentina. 01-05-1853. Artículo 42.
XI. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheuma- toid arthritis to target: results of a systematic literatu- re search update. Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.
XII. Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the tar- get of remission in early rheumatoid arthritis is cost- effective: results of the DREAM registry. BMC Musculos- kelet Disord 2013 Dec 13;14:350.
XIII. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dou- gados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an inter- national task force. Ann Rheum Dis 2016 Jan;75(1):3-15.
XIV. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Working Group Equity in access to treatment of rheumatoid arthritis in Europe. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan;73(1):198-206.
XV. Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, et al. Access to biologic treatment for rheu- matoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011 Apr;17(4):SR1-13.
Published
2022-03-01
How to Cite
1.
Papasidero SB, Medina MA, Bande JM, Caracciolo JA, Klajn DS. Delayed onset of biologic or targeted synthetic dmards in rheumatoid arthritis patients and associated factors. Rev. Argent. Reumatol. [Internet]. 2022Mar.1 [cited 2025May18];33(1):5 - 13. Available from: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/648
Section
Original Article
Copyright (c) 2022 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
